Home Newsfeeds JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $111

JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $111

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.

byBenzinga Newsdesk

September 19, 2022

1 minute read

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.

Barclays Maintains Equal-Weight on Paychex, Lowers Price Target to $115

By Benzinga Newsdesk

December 23, 7:19 AM

Barclays analyst Ramsey El-Assal maintains Paychex (NASDAQ:PAYX) with a Equal-Weight and lowers the price target from $127 to $115.

PAYX

Expion360 Q3 EPS $(0.19) Down From $(0.13) YoY, Sales $1.38M

By Benzinga Newsdesk

November 10, 9:45 AM

Expion360 (NASDAQ:XPON) reported quarterly losses of $(0.19) per share. This is a 46.15 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $1.38 million in sales this

XPON